TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Endometrial pathology in the postmenopausal woman – an evidence based approach to management
Key Statistics
- 60–80% — PMB due to atrophic endometritis/vaginitis
- 5 mm — Standard TVUS abnormal endometrial cut-off
- 2.3% — Malignancy risk, polyp + PMB
Don't-miss facts
-
PMB causes: atrophic endometritis/vaginitis 60–80% · exogenous estrogen 15–25% · carcinoma 10% · hyperplasia 5– 10% · polyps 2–12%
-
Asymptomatic polyp malignancy risk 0.3%; abnormal histology odds ×6.9 if diameter >18 mm – symptomatic polyps always removed, asymptomatic weighed individually
-
Untreated hyperplasia progression: no atypia 2% · atypical 23% · complex atypical 29%
-
LNG-IUS > oral MPA for endometrial regression in complex/atypical hyperplasia (100% vs 96% continuous / 69% cyclical at 6 months)
-
Tamoxifen ↑endometrial thickness 0.75 mm/year; pipelle EMB unreliable – use hysteroscopy + targeted biopsy if symptomatic
-
HRT: investigate only if symptomatic AND thickness >8 mm; PEPI – 5 mm cut-off in asymptomatic users would over- biopsy (>50% for 4% disease)
-
Routine screening of ANY asymptomatic postmenopausal group (general, HRT, tamoxifen) is not recommended – not evidence-based/cost-effective
-
Standard abnormal TVUS threshold = 5 mm; if thickness not visualised in a symptomatic woman → proceed to hysteroscopy (higher cancer odds)
Diagnostic accuracy at a glance
Hysteroscopy+biopsy: sens 100%, spec 97% TVUS: sens 97%, spec 74% (vs hysteroscopic biopsy)
TVS asymptomatic screening: 93.2% false positive
Abbreviation Key
- PMB — postmenopausal bleeding
- LNG-IUS — levonorgestrel-releasing intrauterine system
- TVUS/TVS — transvaginal ultrasound/scan
- MPA — medroxyprogesterone acetate
- SIS — saline infusion sonography
- GnRH — gonadotropin-releasing hormone
- GIS — gel instillation sonography
- PPV/NPV — positive/negative predictive value
- EMB — endometrial biopsy
- PEPI — Postmenopausal Estrogen/Progestogen Interventions trial
- HRT — hormone replacement therapy
- MORE — Multiple Outcomes of Raloxifene Evaluation trial
- SERM — selective estrogen receptor modulator
Source: Otify M et al. Endometrial pathology in the postmenopausal woman – an evidence based approach to management. The Obstetrician & Gynaecologist 2015;17:29–38. doi:10.1111/tog.12150
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).